Use of anti-cd100 antibodies
AssigneeInstitut National De La Sante Et De La Recherche Medicale (Inserm)
InventorsMarie-Francoise Belin, Pascale Giraudon, Laurence Boumsell, Armand Bensussan
Life of this patent
Estimating the term…
Abstract
The invention relates to the use a BD16 and/or BB18 anti-CD100 antibody or of a chimeric or humanized or human form thereof, or a fragment thereof, for the therapy or diagnosis of a central nervous system disorder, more particularly a myelin disorder or a disease that affects oligodendrocytes, such as multiple sclerosis or HTLV-1 associated myelopathy or peripheral myelinating cells.
Claims16
Use of a BD16 and/or BB18 anti-CD100 antibody, or a chimeric or humanized form thereof, or a human anti-CD 100 antibody recognizing similar or closely related epitope(s) to BD16 or BB18, or a fragment thereof, for the preparation of a medicament useful in the prevention or treatment of a central nervous system (CNS) or peripheral nervous system (PNS) inflammatory disorder.
An in vitro method for diagnosis or determination of the evolution of a central (CNS) or peripheral nervous system (PNS) inflammatory disorder, which method comprises assaying a CD100 semaphorin in a biological sample of a test subject, compared with the level of a CD100 semaphorin in a biological sample of a control subject, wherein an increased level of CD100 is indicative of said disorder or of a poor prognosis, wherein the assay is an immunoassay employing a BD16 and/or BB18 anti-CD100 antibody, a chimeric or humanized form thereof, a human anti-CD 100 antibody recognizing similar or closely related epitope(s) to BD16 or BB1, or a fragment thereof.
Dependencies are inferred from the claim text.